 | | Vol. 14.11 – 21 March, 2023 |
| |
|
|
| Scientists uncovered an epigenetic program whereby High mobility group A1 (HMGA1) upregulated FGF19 during tumor progression and stroma formation.
[Journal of Clinical Investigation] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators reported a novel optogenetic regulatory system for insulin secretion in human pluripotent stem cell-derived pancreatic islet-like organoids using monster-opto-Stromal interaction molecule 1.
[Molecular Therapy] |
|
|
|
| The authors investigated the role of Wilms’ tumour 1-associating protein (WTAP) in the regulation of islet beta cell failure and diabetes and generated islet beta cell-specific Wtap-knockout and beta cell-specific Mettl3-overexpressing mice.
[Diabetologia] |
|
|
|
| Scientists investigated the dynamics of elements in the pancreatic islets of a diabetic mouse model expressing human islet amyloid polypeptide.
[Scientific Reports] |
| |
|
|
| By employing an inducible genetic engineered mouse model, the authors illustrated that lineage plasticity enabled advanced PDAC tumors to develop spontaneous relapse following elimination of the central oncogenic driver, Yap.
[Nature Communications] |
|
|
|
| In pancreatic neuroendocrine tumors cells resistant to everolimus, the downregulation of DCAF7 expression overcame resistance and synergized with everolimus to suppress mTOR activation and inhibit cancer cell growth.
[Cancer Research] |
|
|
|
| Researchers identified P2RY2 as the purinergic gene with the strongest association with hypoxia and the strongest impact on overall survival.
[eLife] |
|
|
|
| The authors revealed the relationship between SETD8 and ferroptosis in pancreatic cancer and its role in pancreatic cancer to provide a possible new direction for the comprehensive treatment of pancreatic cancer.
[Cancer Cell International] |
|
|
|
| Scientists explored the association between ferroptosis and glutamine deprivation in pancreatic cancer. The growth of pancreatic cancer cells in culture media with or without glutamine was evaluated using Cell Counting Kit-8.
[Acta Biochimica et Biophysica Sinica] |
|
|
|
|
| Investigators describe current treatment strategies for the various clinical stages of PDAC and discuss developments that are likely to determine the optimal sequence of multimodality therapies.
[Nature Reviews Clinical Oncology] |
|
|
|
|
| Phanes Therapeutics, Inc. announced that the first patient had been dosed in the phase I clinical study of PT886, a first-in-class native IgG-like bispecific antibody targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction, and PDACs.
[Phanes Therapeutics, Inc.] |
|
|
|
|
| April 24 – 26, 2023
Hinxton, England, United Kingdom |
|
|
|
|
|
| | Oslo University Hospital – Oslo, Norway |
|
|
|
| | UCSF Diabetes Center – San Francisco, California, United States |
|
|
|
| | Columbia University – New York City, New York, United States |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Moffitt Cancer Center – Tampa, Florida, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
